A leading biotechnology company that invents life-transforming medicines for people with serious diseases.
our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
REGENERON BY THE NUMBERS
30+ years of scientific leadership
9,000+ employees worldwide
~1,100+ employees with an MD, PhD or PharmD degree
2ND consecutive year as one of Fast Company Best Workplaces for Innovators
#1 ranking in Science magazine’s global Top Employer survey for seven of the past ten years
3,000+ volunteers for virtual Day for Doing Good 2020
8 FDA-approved medicines
98% of our waste diverted from landfill, surpassing our goal
100% of drug candidates invented and developed in-house
1M+ exomes sequencedto date
175+ peer-reviewed publications in 2020
20+ product candidates in clinical development across multiple therapeutic areas